2. Peptides
  3. Peptide and Derivatives
  4. Cell-adhesion Peptides
  5. Laminin peptide CDPGYIGSR TFA

Laminin peptide CDPGYIGSR TFA  (Synonyms: Laminin (925-933) TFA)

Cat. No.: HY-P0131A Purity: 99.75%
COA
SDS
Handling Instructions Technical Support

Laminin peptide CDPGYIGSR (Laminin (925-933)) TFA is a 67 kDa laminin receptor ligand and selective cell adhesion inducer. Laminin peptide CDPGYIGSR TFA not only promotes cell adhesion and mediates directed neurite outgrowth via matrix coating or covalent immobilization, but also inhibits neural crest cell migration under specific conditions. Laminin peptide CDPGYIGSR TFA inhibits lung colonization of melanoma cells, and suppresses the growth of Sarcoma 180 solid tumors and Lewis lung carcinoma (3LL) in mice. Laminin peptide CDPGYIGSR TFA also exerts significant anti-angiogenic effects by inhibiting embryonic angiogenesis in the chick chorioallantoic membrane and vascular endothelial cell migration induced by tumor-conditioned medium. Laminin peptide CDPGYIGSR TFA can be widely used in studies related to melanoma, Sarcoma 180, Lewis lung carcinoma (3LL), and other relevant areas.

For research use only. We do not sell to patients.

Custom Peptide Synthesis

Laminin peptide CDPGYIGSR TFA

Laminin peptide CDPGYIGSR TFA Chemical Structure

CAS No. : 2828432-44-4

Size Price Stock Quantity
5 mg In-stock
10 mg In-stock
50 mg   Get quote  
100 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Other Forms of Laminin peptide CDPGYIGSR TFA:

Laminin peptide CDPGYIGSR TFA Related Antibodies

Top Publications Citing Use of Products

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

Laminin peptide CDPGYIGSR (Laminin (925-933)) TFA is a 67 kDa laminin receptor ligand and selective cell adhesion inducer. Laminin peptide CDPGYIGSR TFA not only promotes cell adhesion and mediates directed neurite outgrowth via matrix coating or covalent immobilization, but also inhibits neural crest cell migration under specific conditions. Laminin peptide CDPGYIGSR TFA inhibits lung colonization of melanoma cells, and suppresses the growth of Sarcoma 180 solid tumors and Lewis lung carcinoma (3LL) in mice. Laminin peptide CDPGYIGSR TFA also exerts significant anti-angiogenic effects by inhibiting embryonic angiogenesis in the chick chorioallantoic membrane and vascular endothelial cell migration induced by tumor-conditioned medium. Laminin peptide CDPGYIGSR TFA can be widely used in studies related to melanoma, Sarcoma 180, Lewis lung carcinoma (3LL), and other relevant areas[1][2][3].

In Vitro

Laminin peptide CDPGYIGSR (TFA) (1 mg/mL; 90 min) only weakly inhibits the adhesion and spreading of RD human rhabdomyosarcoma cells to YIGSR-tSPA-coated substrates[1].
Laminin peptide CDPGYIGSR (TFA) (4 mg; 72 h) spatially restricts NG108-15 cell attachment and neurite outgrowth to the modified regions of patterned 20 μm N-terminus bound CDPGYIGSR pathways on FEP films, with no significant cell interaction on unmodified FEP surfaces over 3 days of culture[2].
Laminin peptide CDPGYIGSR (TFA) (10-9-10-2 M; 7 days) does not affect the in vitro proliferation of human umbilical vein endothelial cells, Sarcoma 180 cells, or Lewis lung carcinoma (3LL) cells[3].
Laminin peptide CDPGYIGSR (TFA) (10-9-10-2 M; 5 hours) dose-dependently inhibits human umbilical vein endothelial cell chemotaxis induced by Sarcoma 180-conditioned medium with an ID50 of 5×10-7 M[3].
Laminin peptide CDPGYIGSR (TFA) (25-200 μg/mL; 2 hours) dose-dependently inhibits human umbilical vein endothelial cell adhesion to laminin, but does not affect adhesion to fibronectin, collagen IV, or gelatin[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Laminin peptide CDPGYIGSR TFA Related Antibodies

Cell Proliferation Assay[3]

Cell Line: human umbilical vein endothelial cells, Sarcoma 180 cells, Lewis lung carcinoma (3LL) cells
Concentration: 10-9 M, 10-8 M, 10-7 M, 10-6 M, 10-5 M, 10-4 M, 10-3 M, 10-2 M
Incubation Time: 7 days (with medium replacement on days 2 and 5)
Result: Exerted no effect on the in vitro proliferation of human umbilical vein endothelial cells, Sarcoma 180 cells, or 3LL cells at any tested concentration.

Cell Migration Assay[3]

Cell Line: human umbilical vein endothelial cells
Concentration: 10-9 M, 10-8 M, 10-7 M, 10-6 M, 10-5 M, 10-4 M, 10-3 M, 10-2 M
Incubation Time: 5 hours
Result: Suppressed endothelial cell chemotaxis induced by Sarcoma 180-conditioned medium in a dose-dependent manner, with an ID50 of 5×10-7 M.
Confirmed via checkerboard analysis the observed endothelial cell migration was chemotactic, not chemokinetic.
In Vivo

Laminin peptide CDPGYIGSR (TFA) (0.1-10 μg; direct application to CAM; single dose) dose-dependently inhibits embryonic CAM angiogenesis with an ID50 of 1.13 μg per egg[3].
Laminin peptide CDPGYIGSR (TFA) (3 mg/head; i.v.; once daily; 4 days) reduces solid Sarcoma 180 tumor weight by ~57% compared to controls, with statistical significance (P < 0.001)[3].
Laminin peptide CDPGYIGSR (TFA) (3 mg/head; i.v.; once daily; 4 days) does not inhibit ascitic Sarcoma 180 tumor growth[3].
Laminin peptide CDPGYIGSR (TFA) (3 mg/head; i.v.; once daily; 10 days) starting 4 days post-3LL cell inoculation reduces lung tumor colony weight by ~81% compared to controls, with statistical significance (P < 0.001)[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: ICR (male, 4 weeks of age, subcutaneous inoculation of 5×106 Sarcoma 180 cells)[3]
Dosage: 3 mg/head
Administration: i.v.; once daily; 4 days
Result: Significantly inhibited solid Sarcoma 180 tumor growth (P < 0.001 versus control).
Reduced mean tumor weight from 438 mg in controls to 187 mg in treated mice.
Achieved ~57% tumor weight reduction compared to controls.
Animal Model: C57BL/6 (male, 4 weeks of age, intravenous inoculation of 5×106 Lewis lung carcinoma (3LL) cells, posttreatment group)[3]
Dosage: 3 mg/head
Administration: i.v.; once daily; 10 days
Result: Significantly reduced lung tumor colony weight compared to controls (P < 0.001).
Lowered mean lung tumor weight from 413 mg in controls to 77 mg in treated mice.
Achieved ~81% lung tumor colony weight reduction compared to controls.
Molecular Weight

1081.08

Formula

C42H63F3N12O16S
CAS No.
Appearance

Solid

Color

White to off-white

Sequence

Cys-Asp-Pro-Gly-Tyr-Ile-Gly-Ser-Arg
Sequence Shortening

CDPGYIGSR
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Sealed storage, away from moisture

Powder -80°C 2 years
-20°C 1 year

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility
In Vitro: 

H2O : 50 mg/mL (46.25 mM; Need ultrasonic)

Preparing
Stock Solutions
Concentration Solvent Mass 1 mg 5 mg 10 mg
1 mM 0.9250 mL 4.6250 mL 9.2500 mL
5 mM 0.1850 mL 0.9250 mL 1.8500 mL
View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • Molarity Calculator

  • Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass
=
Concentration
×
Volume
×
Molecular Weight *

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start)

C1

×
Volume (start)

V1

=
Concentration (final)

C2

×
Volume (final)

V2

In Vivo:

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

  • Protocol 1

    Add each solvent one by one:  PBS

    Solubility: 50 mg/mL (46.25 mM); Clear solution; Need ultrasonic

In Vivo Dissolution Calculator
Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

g

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Calculation results:
Working solution concentration: mg/mL
This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.
The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).
Purity & Documentation

Purity: 99.75%

SDS (254 KB)

COA (250 KB) LCMS (87 KB)

Handling Instructions (2659 KB)
References

Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
H2O 1 mM 0.9250 mL 4.6250 mL 9.2500 mL 23.1250 mL
5 mM 0.1850 mL 0.9250 mL 1.8500 mL 4.6250 mL
10 mM 0.0925 mL 0.4625 mL 0.9250 mL 2.3125 mL
15 mM 0.0617 mL 0.3083 mL 0.6167 mL 1.5417 mL
20 mM 0.0463 mL 0.2313 mL 0.4625 mL 1.1563 mL
25 mM 0.0370 mL 0.1850 mL 0.3700 mL 0.9250 mL
30 mM 0.0308 mL 0.1542 mL 0.3083 mL 0.7708 mL
40 mM 0.0231 mL 0.1156 mL 0.2313 mL 0.5781 mL

* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.

  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

Laminin peptide CDPGYIGSR TFA Related Classifications

Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

Laminin peptide CDPGYIGSR2828432-44-4Laminin (925-933)Othersmelanoma cellsSarcoma 180 tumorschick chorioallantoic membranelaminin receptorneural crest cellsneurite outgrowthneuronal cell differentiationvascular endothelial cellsLewis lung carcinoma (3LL)embryonic angiogenesisInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
Laminin peptide CDPGYIGSR TFA
Cat. No.:
HY-P0131A
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

English - EN (254 KB) Français - FR (254 KB) Deutsch - DE (254 KB) Norwegian - NO (254 KB) Español - ES (254 KB) Swedish - SV (254 KB) Italian - IT (254 KB) Korean - KR (254 KB) Portuguese - PT (254 KB)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.